Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Nov 3, 2009

165_ip_2009-11-03_c04d153a-b831-4a11-b5e0-bf2db0c79d00.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

Third Quarter / Nine Months 2009 Results

Conference Call, November 3, 2009

Forward Looking Statements

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detailed in the Company's reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Agenda

1. Business Update

Third Quarter 2009 - Highlights

Continued strong organic growth of 8% and improving outcomes

Dialysis Services:

  • Continued superior clinical outcomes
  • New Therapies patient growth y-o-y
    • USA Clinic Nocturnal +39%
    • Europe Online Hemodiafiltration +47%
  • Integrated Care expanded +45%

Dialysis Products:

  • Highest quality levels across all production plants and product lines
  • Renal Pharma revenue on target
  • New PD and HD products very well received

Third Quarter 2009 – Overview

Very good third quarter

Q
3
2
0
0
8		 Q
3
2
0
0
9		 G
h
t
r
o
w
R
e
e
n
e
v
u		 \$
2
7
1
3
m
,		 \$
2
8
8
9
m
,		 6
%
+
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
E
A
G
&
Co
K
Ga
A
a		 \$
2
0
6
m		 \$
2
2
5
m		 9
%
+
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
6
9		 \$
0
7
6		 9
%
+
  • •Continued strong revenue growth of +10%cc
  • •Strong sequential EBIT-margin improvement of 50 bps in the third quarter
  • •Improved net income growth of +9%

Nine months 2009 – Overview

Strong performance with ongoing currency headwinds

M
9
2
0
0
8		 M
9
2
0
0
9		 G
t
h
r
o
w
R
e
v
e
n
u
e		 \$
8
9
0
7
m
,		 \$
8
2
1
2
m
,		 4
%
+
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
E
A
G
&
Co
K
Ga
A
a		 \$
6
0
3
m		 \$
6
4
5
m		 7
%
+
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
2
0
3		 \$
2
1
6		 6
%
+

•For the 9M 2009 a total revenue growth of +9%cc and organic growth of +8%

Third Quarter 2009 – Revenue

Total revenue increased 6% to \$2,889 m (10%cc)

Third Quarter 2009 - Dialysis Services Global

Very strong revenue growth globally

\$
S
U
i
i
l
l
i
n
m
o
n
s
-		 Q
3
2
0
0
8		 Q
3
2
0
0
9		 G
t
h
r
o
w		 c
c
i
N
h
A
t
o
r
m
e
r
c
a		 1
5
8
7
,		 1
7
4
1
,		 %
1
0
i
I
l
t
t
n
e
r
n
a
o
n
a		 3
9
8		 4
0
6		 %
2		 %
1
2
T
l
t
o
a		 1
9
8
5
,		 2
1
4
7
,		 8
%		 1
0
%

Treating more than 192,800 patients in ~ 2,510 clinics

Third Quarter 2009 - Dialysis Services Global

Excellent performance in all key metrics

Q
3
2
0
0
9		 T
l
t
o
a		 N
h
A
i
I
i
l
t
t
t
o
r
m
e
r
c
a
n
e
r
n
a
o
n
a
O
i
h
t
r
g
a
n
c
r
e
v
e
n
u
e
g
r
o
w		 8
%
+		 8
%
+		 9
%
+
S
k
t
t
t
t
t
h
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 4
%
+		 4
%
+		 4
%
+
R
t
t
t
e
e
n
e
p
e
r
r
e
a
m
e
n
v
u		 1)
\$
3
4
2		 \$
1
6
7
G
t
h
r
o
w		 4
%
+		 3
%
+
c
c
N
b
f
l
i
i
u
m
e
r
o
c
n
c
s		 2
5
0
9
,		 1
4
9
7
,		 6
0
7
G
h
t
r
o
w		 %
7
+		 %
5
+		 1
1
%
+
D
e
n
o
o
s
v
(
inc
lu
d
ing
d c
l
in
ics
)
m
an
ag
e		 2
3		 1
8		 5

1) including Mexico

Third Quarter 2009 – Revenue per treatment US

Favorable reimbursement trend

Third Quarter 2009 - Quality Outcomes

Overall strong quality performance

N
h
A
i
t
o
r
m
e
r
c
a		 E
M
E
A
%
f
F
M
E
i
t
t
o
p
a
e
n
s		 Q
3
2
0
0
8		 Q
3
2
0
0
9		 Q
3
2
0
0
8		 Q
3
2
0
0
9
K
/
V
1
2
t
≥		 9
5
%		 9
6
%		 9
5
%		 9
5
%
H
l
b
i
1
0
1
2
/
d
l
e
m
o
g
o
n
g
=
-		 8
%
5		 6
4
%		 1
%
5		 5
3
%
/
H
l
b
i
1
0
1
3
d
l
e
m
o
g
o
n
g
=
-		 %
8
6		 8
7
%		 %
7
6		 7
4
%
A
l
b
i
3
/
d
l
5
≥
u
m
n
g		 8
1
%		 8
2
%		 8
%
5		 5
8
%
/
P
h
h
t
3
5
5
5
d
l
o
s
p
a
e
m
g
-		 %
5
3		 5
4
%		 %
6
0		 5
8
%
H
i
l
i
i
d
t
t
o
s
p
a
z
a
o
n
a
y
s		 *
1
0
5		 *
1
0
0		 6
7		 8
7

The hospitalization rates for the US reflects FMS adoption of CMS policy *

Third Quarter 2009 - Dialysis Products

Strong external product growth of 8%cc

\$
S
U
i
i
l
l
i
n
m
o
n
s
-		 Q
3
2
0
0
8		 Q
3
2
0
0
9		 G
t
h
r
o
w		 c
c
T
l
R
t
o
a
e
v
e
n
u
e
(
)
inc
l.
In
ter
l
Re
na
ve
nu
e		 9
4
3		 9
8
8		 %
5		 %
1
1
E
l
R
t
e
r
n
a
e
e
n
e
x
v
u		 2
8
7		 7
4
2		 2
%		 8
%
N
h
A
i
t
o
r
m
e
r
c
a		 1
8
4		 2
0
9		 1
4
%
I
t
t
i
l
n
e
r
n
a
o
n
a		 5
4
4		 5
3
3		 %
2
-		 %
6

Healthcare Reform Initiatives

  • •House bill introduced last week; Senate bill expected this week. Votes expected late November
  • •No cuts anticipated for dialysis providers
  • • Medicare Accountable Care Organization (ACO) and Medicare Special Needs Plans (SNP) reforms remain positive
  • • Specific terms of health exchanges, proposed device industry fee and public plan remain issues to be watched

Bundling – 2011

  • •Comments due November 16; Final rule anticipated Q1 2010
  • • Current assessment:
  • •Insufficient data available to duplicate the CMS analysis
  • •Some areas would result in reimbursement reductions (e.g. case mix, transition adjustment)
  • •Part D oral drugs are significantly underfunded as proposed
  • •Proposed rule does not address coordination of secondary insurance coverage
  • •FME and the dialysis community are working cooperatively with CMS to address these issues

Agenda

2. Financials and Outlook

Third Quarter 2009 - Profit & Loss

\$
i
i
l
l
i
n
m
o
n
s		 Q
3
2
0
0
8		 Q
3
2
0
0
9		 G
t
h
r
o
w
N
t
e
r
e
e
n
e
v
u		 2
7
1
3
,		 2
8
8
9
,		 *
%
6
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 4
2
2		 5
4
1		 7
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
5
6		 1
5
6
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e,
n
e		 8
7		 7
5
f
I
b
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 3
3
5		 3
7
6		 1
2
%
I
T
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 1
2
0		 1
3
1
T
t
a
x
r
a
e		 %
3
6		 %
3
5
N
t
l
l
i
i
t
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 9 2
0
N
i
t
e
n
c
o
m
e
i
bu
b
le
F
M
E
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 2
0
6		 5
2
2		 9
%

* 10% growth at constant currency, 8% organic growth

Nine months 2009 - Profit & Loss

\$
i
i
l
l
i
n
m
o
n
s		 9
M
2
0
0
8		 9
M
2
0
0
9		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 7
8
9
0
,		 8
2
1
2
,		 *
4
%
O
(
)
t
i
i
E
B
I
T
p
e
r
a
n
g
n
c
o
m
e		 1
2
4
0
,		 1
2
6
5
,		 2
%
%
E
B
I
T
i
i
m
a
r
g
n
n		 1
5
7		 1
5
4
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e,
n
e		 2
2
5		 2
2
5
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 9
8
8		 1
0
4
0
,		 %
5
I
T
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 3
5
7		 5
3
4
T
t
a
x
r
a
e		 3
6
%		 3
3
%
N
l
l
i
i
t
t
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 2
8		 5
0
N
t
i
e
n
c
o
m
e
G
&
Co
Ga
t
tr
i
bu
ta
b
le
to
F
M
E
A
K
A
a		 6
0
3		 6
4
5		 %
7

* 9% growth at constant currency, 8% organic growth

Operating Margin Development

Days Sales Outstanding (DSO)

Excellent cash collection in North America

Third Quarter 2009 – Cash Flow

Operating cash flow at 15% of revenue

\$
i
i
l
l
i
n
m
o
n
s		 Q
3
2
0
0
8		 Q
3
2
0
0
9		 G
h
t
r
o
w
1)
O
C
t
i
h
F
l
p
e
r
a
n
g
a
s
o
w		 3
1
5		 4
4
3		 4
1
%
1)
C
i
l
E
d
i
t
t
a
p
a
p
e
n
r
e
s
t
x
u
n
e
,		 (
)
1
6
0		 (
)
1
3
9
C
F
h
F
l
r
e
e
a
s
o
w		 1
5
5		 3
0
4
%
f r
1
1
o
ev
en
ue		 9
%
7
1)
A
i
i
t
i
f
t
d
i
t
i
t
c
q
u
s
o
n
s
n
e
o
e
s
r
e
s
v
u
,		 (
3
9
)		 (
)
2
6
F
C
h
F
l
f
i
i
i
r
e
e
a
s
o
t
t
w
a
e
r
a
c
q
u
s
o
n
s
,		 1
1
6		 2
8
7
1
0
%
f r
o
ev
en
ue

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Nine months 2009 – Cash Flow

Operating cash flow at 11% of revenue

\$
i
i
l
l
i
n
m
o
n
s		 9
M
2
0
0
8		 9
M
2
0
0
9		 G
t
h
r
o
w
1)
O
i
C
h
F
l
t
p
e
r
a
n
g
a
s
o
w		 7
1
6		 8
8
0		 %
2
3
1)
C
i
t
l
E
d
i
t
t
a
p
a
x
p
e
n
u
r
e
s
n
e
,		 (
4
9
3
)		 (
)
3
8
8
F
C
h
F
l
r
e
e
a
s
o
w		 2
2
3		 4
9
2
6
%
f r
o
ev
en
ue		 %
1
2
0
1)
A
i
i
i
t
f
d
i
i
c
q
s
o
n
s
t
t
t
u
n
e
o
v
e
s
u
r
e
s
,		 (
)
1
3
0		 (
)
5
7
C
F
h
F
l
f
t
i
i
t
i
r
e
e
a
s
o
w
a
e
r
a
c
q
s
o
n
s
u
,		 9
3		 4
3
5
%
f r
5
o
ev
en
ue

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Q3 2009 - Debt and EBITDA Development

Debt/EBITDA ratio ahead of target

* including non-cash charges and in 2006/2007 excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Fiscal Year 2009 – Outlook

Improved guidance for 2009

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 O
L
D		 G
i
d
a
n
c
e
u
N
t
R
e
e
v
e
n
u
e
s		 \$
1
1,
1
0
0
>		 \$
1
1
2
0
0
~
,
N
I
t
e
n
c
o
m
e
i
bu
b
le
F
M
E
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 \$
8
5
0
8
9
0
-		 \$
8
6
8
9
0
5
–
L
t
i
e
v
e
r
a
g
e
r
a
o
(
D
b
t
/
E
B
I
T
D
A
)
e		 2
7
<		 2
7
<
C
i
l
E
d
i
t
t
a
p
a
p
e
n
r
e
s
x
u		 \$
5
5
0
6
5
0
~
-		 \$
0
6
0
5
5
5
~
-
A
i
i
t
i
c
q
u
s
o
n
s		 \$
2
0
0
3
0
0
~
-		 \$
2
0
0
2
5
0
~
-

Third Quarter 2009 - Summary

Superior quality performance in both products and services

Continued expansion of new products and therapies worldwide

Strong sequential EBIT- margin improvement

Very strong Cash Flow development

Continued focus on R&D

Upgraded lower end of earnings guidance

3. Questions & Answers

Thank You

for your interest in

Fresenius Medical Care !

Fresenius Medical Care

The World's Leading Renal Therapy Company

Third Quarter / Nine Months 2009 Results

Conference Call, November 3, 2009

Attachment I

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

D
b
t
e		 Q
3
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5
S
(
/
)
ho
bo
ing
inc
l.
A
R
t
te
r
rm
rro
w
s
p
ro
g
ra
m		 3
1
2		 6
8
4		 2
1
7		 3
3
1		 1
5
1
S
ho
t
ter
bo
ing
fro
la
te
d p
t
ies
+
r
m
rro
w
s
m
re
ar		 4
3		 1 2 5 1
9
Cu
t p
t
ion
f
lon
ter
de
b
t a
d c
i
ta
l
lea
b
l
ig
t
ion
+
rre
n
or
o
g-
m
n
ap
se
o
a
s		 1
6
0		 4
5
5		 8
5		 1
6
0		 1
2
6
Cu
ion
f
Tr
Pr
fer
d
Se
i
ies
t p
t
t
t
+
rre
n
or
o
us
e
re
cu
r		 0 6
0
7
Lo
-te
de
b
t a
d c
i
ta
l
lea
b
l
ig
t
ion
+
ng
rm
n
ap
se
o
a
s,
les
t p
t
ion
s c
urr
en
or		 4,
5
6
1		 3,
9
5
7		 4,
0
0
4		 3,
8
2
9		 7
0
7
Tr
t
Pr
fer
d
Se
i
t
ies
(
t o
f c
t p
t
ion
)
+
us
e
re
cu
r
ne
urr
en
or		 6
6
3		 6
4
1		 6
6
4		 1,
2
5
4		 1,
1
8
8
To
l
de
b
ta
t
=		 5,
3
9
7		 5,
3
8
7		 5,
6
4
2		 5,
5
9
7		 2,
1
9
1
E
B
I
T
D
A		 Q
3
2
0
0
9		 Q
3
2
0
0
8		 F
Y
2
0
0
8		 1)
F
Y
2
0
0
7		 F
Y
2
0
0
6
(pr
o
for
)
ma		 F
Y
2
0
0
5
(
)
La
lve
hs
ing
inc
E
B
I
T
t
tw
t
t
s
e
m
on
o
p
er
a
om
e		 1,
6
9
7		 1,
6
6
8		 1,
6
7
2		 1,
5
8
0		 1,
3
6
7		 9
3
9
La
t
tw
lve
t
hs
de
ia
t
ion
d a
t
iza
t
ion
+
s
e
m
on
p
rec
an
mo
r		 4
4
3		 4
1
0		 4
1
6		 3
6
3		 3
2
6		 2
1
5
No
h c
ha
+
n-c
as
rg
es		 4
8		 4
4		 4
4		 4
1		 3
5		 1
4
E
B
I
T
D
A
(
l
ize
d
)
an
nu
a
=		 2,
1
8
8		 2,
1
2
2		 2,
1
3
2		 1,
9
8
4		 1,
7
2
8		 1,
2
0
4

1) Excluding restructuring costs and in-process R&D

Attachment II

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

E
l
R
t
x
e
r
n
a
e
v
e
n
u
e
C
i
l
d
i
(
)
t
t
t
a
p
a
e
x
p
e
n
u
r
e
n
e		 M
9
2
0
0
9		 M
9
2
0
0
8		 Q
3
2
0
0
9		 Q
3
2
0
0
8
Pu
ha
f p
lan
d e
ip
ty,
t a
t
rc
se
o
ro
p
er
p
n
q
u
me
n		 (
3
9
8
)		 (
5
0
2
)		 (
1
4
5
)		 (
1
6
0
)
Pr
ds
fro
le
f p
lan
d e
ip
ty,
t a
t
oc
ee
m
sa
o
ro
p
er
p
n
q
me
n
u
-		 1
0		 9 6 (
0
)
Ca
i
l e
d
i
(
)
ta
tu
t
p
xp
en
re
ne
=		 (
3
8
8
)		 (
4
9
3
)		 (
1
3
9
)		 (
1
6
0
)
C
h
F
l
a
s
o
w		 M
9
2
0
0
9		 M
9
2
0
0
8		 Q
3
2
0
0
9		 Q
3
2
0
0
8
Ac
is
i
t
ion
d
Inv
tm
t a
d
t p
ha
f
in
ta
i
b
le
ts
q
u
s a
n
es
en
n
ne
ur
c
se
s o
ng
as
se		 (
1
0
9
)		 (
1
7
6
)		 (
2
7
)		 (
4
4
)
fro
Pr
ds
d
ive
t
i
tu
oc
ee
m
s
re
s		 5
2		 4
6		 1 5
is
i
io
f
ive
i
Ac
d
t
t o
t
tu
q
ns
ne
s
re
s
u
,		 (
)
5
7		 (
)
1
3
0		 (
)
2
6		 (
)
3
9

All numbers are in \$ millions

Dialysis Services - Global

9
M
2
0
0
9		 C
i
i
l
n
c		 i
P
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
ion
)
m
T
t
l
o
a		 2
5
0
9
,		 1
9
2
8
0
4
,		 2
1
8
G
t
h
r
o
w		 %
7
+		 %
6
+		 %
6
+
N
h
A
i
t
o
r
m
e
r
c
a		 1
4
9
7
,		 1
3
0
2
2
5
,		 1
4
8
G
h
t
r
o
w		 %
5
+		 4
%
+		 4
%
+
I
i
l
t
t
n
e
r
n
a
o
n
a		 6
0
7		 6
2
2
8
2
,		 1
7
G
t
h
r
o
w		 %
1
1
+		 %
1
0
+		 %
1
0
+
E
u
r
o
p
e		 4
2
7		 3
1,
4
3
1		 3
6
L
t
i
A
i
a
n
m
e
r
c
a		 1
9
3		 2
0,
8
3
4		 2
4
A
i
P
i
f
i
s
a-
a
c
c		 1
4
0		 1
0,
0
1
7		 1.
1

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse Kröner Str. 161352 Bad Homburg v.d.H.

Ordinary shares WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

Oliver Maier

Head of Investor Relations & Corporate Communications

Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 Email: [email protected]

Gerrit Jost

Tel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 Email: [email protected]

Terry L. Morris

Tel.: +1-800-948-2538Fax.: +1-615-345-5605Email: [email protected]

Q4 and Full Year Results 2009 – February 23, 2010

For recent updates, please have a look at our webpage. Navigation around www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ... Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ... Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data … Investor Relations > Our Share

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.